

Frank Hoentjen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10074257/publications.pdf>

Version: 2024-02-01

141
papers

3,288
citations

218677

26
h-index

182427

51
g-index

143
all docs

143
docs citations

143
times ranked

4236
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Reduction of Colitis by Prebiotics in HLA-B27 Transgenic Rats Is Associated with Microflora Changes and Immunomodulation. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 977-985. | 1.9 | 179 |
| 2 | IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. <i>Nature Communications</i> , 2018, 9, 2427. | 12.8 | 159 |
| 3 | STAT3 regulates NF- κ B recruitment to the IL-12p40 promoter in dendritic cells. <i>Blood</i> , 2005, 105, 689-696. | 1.4 | 145 |
| 4 | Clinical Outcomes Following a Switch from Remicade [®] to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1287-1293. | 1.3 | 124 |
| 5 | Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 33-45. | 1.3 | 124 |
| 6 | Prior Colorectal Neoplasia Is Associated With Increased Risk of Ileoanal Pouch Neoplasia in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2014, 146, 119-128.e1. | 1.3 | 113 |
| 7 | Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2021, 160, 1584-1598. | 1.3 | 113 |
| 8 | Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2067. | 3.3 | 100 |
| 9 | Probiotics and prebiotics in ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 55-71. | 2.4 | 92 |
| 10 | Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 123-134. | 3.7 | 92 |
| 11 | Safety and Effectiveness of Long-term Allopurinol Thiopurine Maintenance Treatment in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 363-369. | 1.9 | 89 |
| 12 | Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 129-138. | 3.7 | 87 |
| 13 | Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 997-1006.e6. | 1.3 | 86 |
| 14 | Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 149-158. | 1.3 | 85 |
| 15 | Infectious Proctitis: When to Suspect It Is Not Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 269-273. | 2.3 | 76 |
| 16 | Epstein-Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 398-403. | 1.3 | 70 |
| 17 | Risk of Neoplasia After Colectomy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 798-806.e20. | 4.4 | 68 |
| 18 | Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 880-888. | 3.7 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Long-Term Clinical Outcomes After Switching from Remicade [®] to Biosimilar CT-P13 in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3117-3122. | 2.3 | 61 |
| 20 | Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 529-539. | 1.3 | 60 |
| 21 | Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1298-1306. | 1.9 | 53 |
| 22 | TNF- α -induced protein 3 (TNFAIP3) /A20 acts as a master switch in TNF- α blockade-driven IL-17A expression. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 517-529. | 2.9 | 52 |
| 23 | Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 135-142. | 3.7 | 51 |
| 24 | Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. <i>Gut</i> , 2021, 70, 1266-1274. | 12.1 | 40 |
| 25 | Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. <i>BMJ Open</i> , 2017, 7, e016695. | 1.9 | 33 |
| 26 | Healthy Cotwins Share Gut Microbiome Signatures With Their Inflammatory Bowel Disease Twins and Unrelated Patients. <i>Gastroenterology</i> , 2021, 160, 1970-1985. | 1.3 | 31 |
| 27 | WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. <i>World Journal of Emergency Surgery</i> , 2021, 16, 23. | 5.0 | 29 |
| 28 | Adenosine is a negative regulator of NF- κ B and MAPK signaling in human intestinal epithelial cells. <i>Cellular Immunology</i> , 2005, 237, 86-95. | 3.0 | 28 |
| 29 | Long-term Risk of Advanced Neoplasia After Colonic Low-grade Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1485-1491. | 1.3 | 28 |
| 30 | Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1366-1376. | 3.7 | 28 |
| 31 | Long-term Treatment of Patients With a History of Ulcerative Colitis Who Develop Gastritis and Pan-Enteritis After Colectomy. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 52-57. | 2.2 | 27 |
| 32 | Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study. <i>Gut</i> , 2019, 68, 615-622. | 12.1 | 27 |
| 33 | Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 480-489. | 1.3 | 26 |
| 34 | Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 425-431. | 1.3 | 24 |
| 35 | Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 172-179. | 1.9 | 24 |
| 36 | Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1189-1199. | 4.7 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. <i>United European Gastroenterology Journal</i> , 2021, 9, 1136-1147. | 3.8 | 24 |
| 38 | Golimumab for the treatment of ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 53. | 2.3 | 22 |
| 39 | Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1920-1930. | 1.3 | 22 |
| 40 | Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. <i>Frontiers in Immunology</i> , 2021, 12, 768957. | 4.8 | 22 |
| 41 | Dysregulated luminal bacterial antigen-specific T-cell responses and antigen-presenting cell function in HLA-B27 transgenic rats with chronic colitis. <i>Immunology</i> , 2005, 116, 112-121. | 4.4 | 21 |
| 42 | CD4+ T lymphocytes mediate colitis in HLA-B27 transgenic rats monoassociated with nonpathogenic <i>Bacteroides vulgatus</i> . <i>Inflammatory Bowel Diseases</i> , 2007, 13, 317-324. | 1.9 | 21 |
| 43 | Clinical experience and diagnostic algorithm of vulval Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 838-843. | 1.6 | 21 |
| 44 | Malignant and Nonmalignant Complications of the Rectal Stump in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 377-384. | 1.9 | 21 |
| 45 | Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease. <i>Annals of Surgery</i> , 2021, 273, 557-563. | 4.2 | 21 |
| 46 | Colorectal Cancer Risk in Patients With Lynch Syndrome and Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 454-458.e1. | 4.4 | 20 |
| 47 | Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. <i>Drug Safety</i> , 2020, 43, 917-925. | 3.2 | 20 |
| 48 | High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1573-1582.e5. | 4.4 | 20 |
| 49 | Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2018-2026. | 1.9 | 19 |
| 50 | Update on the Management of Ulcerative Colitis. <i>Current Gastroenterology Reports</i> , 2011, 13, 475-485. | 2.5 | 18 |
| 51 | Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes. <i>United European Gastroenterology Journal</i> , 2020, 8, 1031-1044. | 3.8 | 18 |
| 52 | A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1076-1086. | 3.7 | 18 |
| 53 | Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 155-161. | 1.5 | 18 |
| 54 | Proinflammatory Cytokines and Signaling Pathways in Intestinal Innate Immune Cells. , 2005, , 681-701. | | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1954-1962. | 1.9 | 17 |
| 56 | Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 182-191.e2. | 4.4 | 17 |
| 57 | Controversies in Pouch Surveillance for Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 747-751. | 1.3 | 16 |
| 58 | Elective Switching from Infliximab to Adalimumab in Stable Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 761-766. | 1.9 | 15 |
| 59 | Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 568-570. | 4.4 | 15 |
| 60 | No Increased Risk of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease and Postinflammatory Polyps. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1383-1389. | 1.9 | 15 |
| 61 | Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 431-440. | 0.9 | 15 |
| 62 | Complications of Peristomal Recurrence of Crohn's Disease. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2012, 39, 297-301. | 1.0 | 14 |
| 63 | Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2015-2026. | 1.9 | 14 |
| 64 | Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 465-471. | 0.9 | 14 |
| 65 | Better survival of renal cell carcinoma in patients with inflammatory bowel disease. <i>Oncotarget</i> , 2015, 6, 38336-38347. | 1.8 | 14 |
| 66 | Allopurinol and 5-aminosalicylic acid influence thiopurine-induced hepatotoxicity in vitro. <i>Cell Biology and Toxicology</i> , 2015, 31, 161-171. | 5.3 | 13 |
| 67 | Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 159-165. | 1.3 | 13 |
| 68 | Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry. <i>Drug Safety</i> , 2021, 44, 581-588. | 3.2 | 13 |
| 69 | Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor- α during pregnancy: A systemic review and meta-analysis. <i>Journal of Autoimmunity</i> , 2021, 122, 102676. | 6.5 | 13 |
| 70 | Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy. <i>United European Gastroenterology Journal</i> , 2021, 9, 919-928. | 3.8 | 12 |
| 71 | Is the prevalence of colonic neuroendocrine tumors increased in patients with inflammatory bowel disease?. <i>International Journal of Cancer</i> , 2016, 139, 535-542. | 5.1 | 11 |
| 72 | Reduction in Inflammatory Bowel Disease Healthcare During the Coronavirus Disease 2019 Pandemic: A Nationwide Retrospective Cohort Study. <i>Gastroenterology</i> , 2021, 160, 935-937.e1. | 1.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | GST Theta null genotype is associated with an increased risk for ulcerative colitis: a case-control study and meta-analysis of GST Mu and GST Theta polymorphisms in inflammatory bowel disease. <i>Journal of Human Genetics</i> , 2014, 59, 575-580. | 2.3 | 10 |
| 74 | Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 689-699. | 1.9 | 9 |
| 75 | Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction. <i>Digestive Diseases and Sciences</i> , 2012, 57, 250-253. | 2.3 | 8 |
| 76 | Increased risk of high-grade dysplasia and colorectal cancer in inflammatory bowel disease patients with recurrent low-grade dysplasia. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 1334-1342.e1. | 1.0 | 8 |
| 77 | LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease. <i>PLoS ONE</i> , 2015, 10, e0133932. | 2.5 | 8 |
| 78 | Severe exacerbation of Crohn's disease during sunitinib treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 234-236. | 1.6 | 7 |
| 79 | Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1558-1565. | 1.9 | 7 |
| 80 | Inflammatory bowel disease patients provide reliable self-reported medical information: A multicentre prospective pharmacovigilance monitoring system. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 520-524. | 1.9 | 7 |
| 81 | Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?. <i>Acta Oncologica</i> , 2016, 55, 444-448. | 1.8 | 6 |
| 82 | Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1293-1300. | 3.7 | 6 |
| 83 | Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2020, 382, 92-94. | 27.0 | 6 |
| 84 | Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1049-1054. | 2.4 | 6 |
| 85 | Management of Crohn's disease in poor responders to adalimumab. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 83. | 2.3 | 5 |
| 86 | Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 177-179. | 1.2 | 5 |
| 87 | Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 477-481. | 2.4 | 5 |
| 88 | Short article: Recommendations on rectal surveillance for colorectal cancer after subtotal colectomy in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 843-846. | 1.6 | 5 |
| 89 | Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e783-e788. | 1.6 | 5 |
| 90 | Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 699-706. | 2.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1813-1820. | 1.9 | 5 |
| 92 | Increased Colorectal Neoplasia Risk in Patients with Inflammatory Bowel Disease and Serrated Polyps with Dysplasia. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5647-5656. | 2.3 | 5 |
| 93 | Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 940-945. | 1.3 | 5 |
| 94 | Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 597-599. | 0.9 | 5 |
| 95 | Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1060-1067. | 1.9 | 3 |
| 96 | Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn's Disease Patients: A Case Report and Review of the Literature. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 162-164. | 1.3 | 3 |
| 97 | Pathophysiology of Inflammatory Bowel Diseases. , 2008, , 341-373. | | 2 |
| 98 | Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1521-1528. | 2.4 | 2 |
| 99 | Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. <i>Journal of Rheumatology</i> , 2021, 48, 1388-1394. | 2.0 | 2 |
| 100 | De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, . | 1.6 | 2 |
| 101 | Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West. <i>Inflammatory Bowel Diseases</i> , 2022, 28, S16-S24. | 1.9 | 2 |
| 102 | Effect of circulating peptide YY on gallbladder motility in response to feeding in humans. <i>Gastroenterology</i> , 2001, 120, A14. | 1.3 | 1 |
| 103 | Antibiotics with a selective aerobic and anaerobic spectrum have different therapeutic activities in various regions of the colon in IL-10 knock-out mice. <i>Gastroenterology</i> , 2001, 120, A687. | 1.3 | 1 |
| 104 | Dysregulated luminal bacterial antigen-specific T cell responses and antigen presenting cell function in HLA-B27 transgenic rats with chronic colitis. <i>Gastroenterology</i> , 2003, 124, A487. | 1.3 | 1 |
| 105 | Allopurinol-thiopurine combination therapy in inflammatory bowel disease. <i>Clinical Investigation</i> , 2014, 4, 873-879. | 0.0 | 1 |
| 106 | Mo1896 - Ustekinumab for Crohn's Disease: A Nationwide Real-Life Observational Cohort Study (ICC) Tj ETQq0 0 0 rgBT /Overlock 10 TF | 1.3 | 1 |
| 107 | Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure—getting closer to the truth. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1255-1256. | 3.7 | 1 |
| 108 | Type C Mucosa in Pouch Surveillance: How Real is the Risk?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1180-1180. | 1.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Different cytokine profiles in mesenteric lymph node cells from HLA-B27 transgenic versus wild type rats stimulated with cecal bacterial antigen. <i>Gastroenterology</i> , 2001, 120, A516. | 1.3 | 0 |
| 110 | B cells produce immunoregulatory molecules in both HLA-B27 transgenic rats with colitis and non-transgenic littermates. <i>Gastroenterology</i> , 2003, 124, A487. | 1.3 | 0 |
| 111 | 268 An Elective Switch From Infliximab to Adalimumab in Quiescent Crohn's Disease is Safe and Effective. <i>Gastroenterology</i> , 2012, 142, S-64. | 1.3 | 0 |
| 112 | Mo1669 Renal Cell Carcinoma Patients Have a Better Survival in a Nationwide Inflammatory Bowel Disease Cohort Compared With the General Population. <i>Gastroenterology</i> , 2014, 146, S-631-S-632. | 1.3 | 0 |
| 113 | Tu1936 Case-Control Study and Meta-Analysis of Glutathione S-Transferase Polymorphisms in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2014, 146, S-876. | 1.3 | 0 |
| 114 | Su1114 Intestinal Epstein-Barr Virus Is Associated With Mucosal Lymphoproliferation and Subsequent Intestinal Surgery in Inflammatory Bowel Disease Patients. <i>Gastroenterology</i> , 2014, 146, S-378-S-379. | 1.3 | 0 |
| 115 | Mo1190 Co-Administration of 5-Aminosalicylic Acid to 6-Mercaptopurine Reduces In Vitro Hepatotoxicity. <i>Gastroenterology</i> , 2014, 146, S-582. | 1.3 | 0 |
| 116 | Mo1196 In Vitro Pancreas Toxicity by Azathioprine but Not 6-Mercaptopurine. <i>Gastroenterology</i> , 2014, 146, S-583. | 1.3 | 0 |
| 117 | Cuff and Pouch Cancer in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, E20. | 1.9 | 0 |
| 118 | Su1307 Neoplasia Risk After Colectomy in Inflammatory Bowel Disease Patients - A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2015, 148, S-469. | 1.3 | 0 |
| 119 | Switching From Remicade [®] to Biosimilar ct-P13 in Inflammatory Bowel Disease Patients: One Year Follow-Up of a Prospective Observational Cohort Study. <i>Gastroenterology</i> , 2017, 152, S587. | 1.3 | 0 |
| 120 | Sa1738 - Thiopurines Versus Anti-TNF [±] for the Prevention of Postoperative Recurrence in Crohn's Disease - A Metaanalysis. <i>Gastroenterology</i> , 2018, 154, S-375-S-376. | 1.3 | 0 |
| 121 | Mo1884 - Drug Survival of Vedolizumab-Treated Inflammatory Bowel Disease Patients in a Nationwide Observational Cohort Study: ICC Case Series. <i>Gastroenterology</i> , 2018, 154, S-838. | 1.3 | 0 |
| 122 | 162 - Long-Term Risk of Advanced Neoplasia after Colonic Low-Grade Dysplasia in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Gastroenterology</i> , 2018, 154, S-45. | 1.3 | 0 |
| 123 | Mo1844 - Drug Survival and Immunogenicity after Switching from Remicade [®] to Biosimilar Ct-P13 in Inflammatory Bowel Disease Patients: Two Year Follow-Up of a Prospective Observational Cohort Study. <i>Gastroenterology</i> , 2018, 154, S-822. | 1.3 | 0 |
| 124 | Su1837 " Higher Discontinuation Rates of Anti-TNF Therapy in Elderly IBD Patients Compared to a Younger Age Group: Results from a Prospective Registry. <i>Gastroenterology</i> , 2019, 156, S-629. | 1.3 | 0 |
| 125 | Mo1845 " Increased Risk of Advanced Neoplasia in Inflammatory Bowel Disease Patients with Recurrent Low-Grade Dysplasia. <i>Gastroenterology</i> , 2019, 156, S-859. | 1.3 | 0 |
| 126 | Mo1818 COLORECTAL NEOPLASIA RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND SERRATED LESIONS. <i>Gastroenterology</i> , 2020, 158, S-936. | 1.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease—what about mucosal healing and biomarkers? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 753-754. | 3.7 | 0 |
| 128 | Sa1742 THIOPURINE AND LOW DOSE THIOPURINES AND ALLOPURINOL ARE BOTH SAFE OPTIONS AFTER FAILURE OF CONVENTIONAL THIOPURINES: A COMPARATIVE ANALYSIS OF TWO MULTICENTER COHORTS. <i>Gastroenterology</i> , 2020, 158, S-405. | 1.3 | 0 |
| 129 | Noninferiority or Nonsuperiority?. <i>Gastroenterology</i> , 2020, 159, 2248. | 1.3 | 0 |
| 130 | Letter: tofacitinib in treatment—refractory ulcerative colitis—a single centre real—world experience in Australia. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 534-535. | 3.7 | 0 |
| 131 | Patients—™ perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8. | 2.4 | 0 |
| 132 | Digestive Disease Week 2011: —An Update on IBD Clinical Research. <i>International Journal of Clinical Reviews</i> , 0, , . | 0.1 | 0 |
| 133 | Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction. <i>American Journal of Gastroenterology</i> , 2011, 106, S354. | 0.4 | 0 |
| 134 | Pan-enteritis in Patients with a History of Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2011, 106, S353-S354. | 0.4 | 0 |
| 135 | Long-term Effectiveness and Tolerability of Allopurinol and Thiopurine Combination Therapy in Inflammatory Bowel Disease Patients: 2011 ACG IBD Award. <i>American Journal of Gastroenterology</i> , 2011, 106, S438-S439. | 0.4 | 0 |
| 136 | Biologic Therapy of Crohn—™s Disease: Infliximab. , 2012, , 413-432. | | 0 |
| 137 | Update on Conventional Thiopurine Management in IBD. <i>International Journal of Clinical Reviews</i> , 0, , . | 0.1 | 0 |
| 138 | A biopsy-guided analysis of diarrhea in patients treated with tyrosine kinase inhibitors of the vascular endothelial growth factor receptor.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15596-e15596. | 1.6 | 0 |
| 139 | Editorial: <sc>anti—TNF</sc> combination therapy for inflammatory bowel disease—“one size does not fit all. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 750-751. | 3.7 | 0 |
| 140 | Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1617-1618. | 3.7 | 0 |
| 141 | Confirming effectiveness of endoscopic colon cancer screening in IBD: the puzzle remains unsolved?. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , . | 4.4 | 0 |